Amsacrine combined with etoposide and methylprednisolone is a feasible and safe component in first‐line intensified treatment of pediatric patients with high‐risk acute lymphoblastic leukemia in CoALL08‐09 trial

Mezger, Kerstin; Ebert, Sabine; Muhle, Hannah Elisa; Stadt, Udo zur; Dilloo, Dagmar; Faber, Jörg; Feuchtinger, Tobias; Imschweiler, Thomas; Jorch, Norbert; Pekrun, Arnulf; Schmid, Irene; Schramm, Franziska; Zimmermann, Martin; Horstmann, Martin; Escherich, Gabriele

doi:10.1002/pbc.29997

Cited by 4 publications

(5 citation statements)

References 45 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Shown in Figure 5 are some 4-amino-quinoline drugs and drug candidates such as Chloroquine, Amodiaquine, Bosutinib, Amsacrine, and Dovitinib for the treatment of malarial [ 148 , 149 , 150 ], leukemia [ 151 , 152 ], and cancer diseases [ 153 ]. Common methods in the literature for the synthesis of 4-aminoquinolines are aniline-based multi-step reactions [ 96 , 154 , 155 , 156 ].…”

Section: Resultsmentioning

confidence: 99%

2-Azidobenzaldehyde-Based [4+2] Annulation for the Synthesis of Quinoline Derivatives

Zhang,

Liu,

Qiu

et al. 2024

Molecules

View full text Add to dashboard Cite

Quinoline is a privileged heterocyclic ring which can be found in many drug molecules and bioactive compounds. The development of synthetic methods for making quinoline derivatives continuously attracts the interest of organic and medicinal chemists. This paper highlights 2-azidobenzaldehyde-based [4+2] annulation for the synthesis of quinoline derivatives including fused and spiro-quinolines, quinoline-4-ols, 4-aminoquinolines, and related compounds.

show abstract

Section: Resultsmentioning

confidence: 99%

2-Azidobenzaldehyde-Based [4+2] Annulation for the Synthesis of Quinoline Derivatives

Zhang,

Liu,

Qiu

et al. 2024

Molecules

View full text Add to dashboard Cite

show abstract

“…Prednisone, a popular glucocorticoid, has emerged as the standard treatment for individuals diagnosed with acute lymphoblastic leukemia (ALL). Typically administered for a duration of four consecutive weeks, it is complemented by a combination of other chemotherapy drugs [121], [141], [142].…”

Section: Leukemia Treatmentsmentioning

confidence: 99%

Trending Drugs Combination to Target Leukemia associated Proteins/Genes: using Graph Neural Networks under the RAIN Protocol

Boush,

Kiaei,

Mahboubi

2023

Preprint

View full text Add to dashboard Cite

BackgroundLeukemia, a cancer impacting blood-forming tissues such as bone marrow and the lymphatic system, presents in various forms, affecting children and adults differently. The therapeutic approach is complex and depends on the specific leukemia type. Effective management is crucial as it disrupts normal blood cell production, increasing infection susceptibility. Treatments like chemotherapy can further weaken immunity. Thus, a patient’s healthcare plan should focus on comfort, reducing chemotherapy side effects, protecting veins, addressing complications, and offering educational and emotional support.MethodThis article reviews studies on the combined use of drugs for treating leukemia. Employing a mix of medicines might decrease the chances of tumor resistance. Starting multiple drugs concurrently allows for immediate application during disease onset, avoiding delays. Initial chemotherapy uses a drug combination to eliminate maximum leukemia cells and restore normal blood counts. Afterwards, intensification chemotherapy targets any residual, undetectable leukemia cells in the blood or bone marrow. To recommend a drug combination to treat/manage Leukemia, under first step of RAIN protocol, we have searched articles including related trend drugs using Natural Language Processing. In the second step, we have employed Graph Neural Network to pass information between these trending drugs and genes that act as potential targets for Leukemia.ResultAs a result, the Graph Neural network recommends combining Tretinoin, Asparaginase, and Cytarabine. The network meta-analysis confirmed the effectiveness of these drugs on associated genes.ConclusionThe p-value between leukemia and the scenario that includes combinations of the mentioned drugs is almost zero, indicating an improvement in leukemia treatment. Reviews of clinical trials on these medications support this claim.HighlightsCombined drugs that make p-value between Leukemia and target proteins/genes close to 1Using Graph Neural network to recommend drug combinationA Network meta-analysis to measure the comparative efficacyConsidered drug interactions

show abstract

“…Amsacrine (4 0 -(9-Acridinylamino)methanesulfon-m-anisidide) is a potent anticancer drug belonging to the anthracenedione family. It is widely used in the treatment of various types of cancers, including acute myeloid leukemia, solid tumors and lymphomas (Mezger et al, 2022;Zhang et al, 2019). The clinical efficacy of amsacrine is attributed to its ability to intercalate DNA, inhibit topoisomerase II activity and induce apoptosis in cancer cells.…”

Section: Introductionmentioning

confidence: 99%

“…Amsacrine (4′-(9-Acridinylamino)methanesulfon-m-anisidide) is a potent anticancer drug belonging to the anthracenedione family. It is widely used in the treatment of various types of cancers, including acute myeloid leukemia, solid tumors and lymphomas (Mezger et al. , 2022; Zhang et al.…”

Section: Introductionmentioning

confidence: 99%

A molecular imprinting electrochemical sensor for detection of anticancer drug amsacrine

Zhang,

Zhang

2024

View full text Add to dashboard Cite

Purpose The purpose of this study is to develop a molecular imprinting electrochemical sensor for the specific detection of the anticancer drug amsacrine. The sensor used a composite of bacterial cellulose (BC) and silver nanoparticles (AgNPs) as a platform for the immobilization of a molecularly imprinted polymer (MIP) film. The main objective was to enhance the electrochemical properties of the sensor and achieve a high level of selectivity and sensitivity toward amsacrine molecules in complex biological samples. Design/methodology/approach The composite of BC-AgNPs was synthesized and characterized using FTIR, XRD and SEM techniques. The MIP film was molecularly imprinted to selectively bind amsacrine molecules. Electrochemical characterization, including cyclic voltammetry and electrochemical impedance spectroscopy, was performed to evaluate the modified electrode’s conductivity and electron transfer compared to the bare glassy carbon electrode (GCE). Differential pulse voltammetry was used for quantitative detection of amsacrine in the concentration range of 30–110 µM. Findings The developed molecular imprinting electrochemical sensor demonstrated significant improvements in conductivity and electron transfer compared to the bare GCE. The sensor exhibited a linear response to amsacrine concentrations between 30 and 110 µM, with a low limit of detection of 1.51 µM. The electrochemical response of the sensor showed remarkable changes before and after amsacrine binding, indicating the successful imprinting of amsacrine in the MIP film. The sensor displayed excellent selectivity for amsacrine in the presence of interfering substances, and it exhibited good stability and reproducibility. Originality/value This study presents a novel molecular imprinting electrochemical sensor design using a composite of BC and AgNPs as a platform for MIP film immobilization. The incorporation of BC-AgNPs improved the sensor’s electrochemical properties, leading to enhanced sensitivity and selectivity for amsacrine detection. The successful imprinting of amsacrine in the MIP film contributes to the sensor's specificity. The sensor's ability to detect amsacrine in a concentration range relevant to anticancer therapy and its excellent performance in complex sample matrices add significant value to the field of electrochemical sensing for pharmaceutical analysis.

show abstract

Amsacrine combined with etoposide and methylprednisolone is a feasible and safe component in first‐line intensified treatment of pediatric patients with high‐risk acute lymphoblastic leukemia in CoALL08‐09 trial

Cited by 4 publications

References 45 publications

2-Azidobenzaldehyde-Based [4+2] Annulation for the Synthesis of Quinoline Derivatives

2-Azidobenzaldehyde-Based [4+2] Annulation for the Synthesis of Quinoline Derivatives

Trending Drugs Combination to Target Leukemia associated Proteins/Genes: using Graph Neural Networks under the RAIN Protocol

A molecular imprinting electrochemical sensor for detection of anticancer drug amsacrine

Contact Info

Product

Resources

About